An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
A Phase 1, Open-label trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection with or without Intramural Injection in Subjects with Bladder Cancer
ResQ133a-NMIBC: Phase 1/2 Clinical Trial Of Intra Vesical Recombinant Mycobacterium (RMBCG) In Participants With NMIBC Eligible To Receive Intra Vesical Tice BCG
Reoccurrence of NMIBC – High Grade After 1 Induction of BCG
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants with High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Reoccurrence of NMIBC – High Grade Ta/T1 after adequate BCG
A phase 2, randomized, multi-centre, open-label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer
